Mobile website
Clinical Research
Influence of liver metastasis on the effectiveness of immunotherapy in patients with gastric cancer: a retrospective cohort study
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To explore the impact of liver metastasis on immunotherapy efficacy in patients with advanced gastric cancer.Methods: From February 2019 to January 2022, clinical data of patients with advanced gastric cancer who received immunotherapy in the Cancer Center of Changzhou No.2 People's Hospital affiliated to Nanjing Medical University were collected for this retrospective analysis. The baseline characteristics were compared by Chi-square test or Fisher exact probability method. Chi-square test and KaplanMeier survival analysis were used to compare the therapeutic efficacy and survival time between gastric cancer patients with and without liver metastasis. Results: A total of 48 patients with advanced gastric cancer were included in the analysis, and the patients were divided into a liver metastasis cohort (n=20) and a non-liver metastasis cohort (n=28). The physical condition of patients with liver metastasis was worse than those without liver metastasis. The objective response rates (ORR) in metastasis cohort and non-metastasis cohort were 15.0% and 35.7% (P>0.05), respectively; and the disease control rates (DCR) in these two cohorts were 65.0% and 82.1% (P>0.05), respectively. The median progression-free survival (PFS) was 5.0 and 11.2 months in the two groups (HR=0.40, P<0.05), and the median overall survival (OS) was 12.0 and 19.0 months (P>0.05), respectively. Conclusion: The efficacy of immunotherapy in gastric cancer patients with liver metastasis is worse than that in patients without liver metastasis.
Keywords:
Project Supported:
Clc Number:
